Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-18), BeOne Medicines's 3-1 Month Momentum % is -2.48%.
The industry rank for BeOne Medicines's 3-1 Month Momentum % or its related term are showing as below:
BEIGF's 3-1 Month Momentum % is ranked better than 65.32% of 1387
companies
in the Biotechnology industry
Industry Median: -8.01
vs BEIGF: -2.48
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
BeOne Medicines 3-1 Month Momentum % Related Terms
BEIGF vs ALNY, RVMD, RPRX: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, BeOne Medicines's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines (BEIGF) has a 3-1 Month Momentum % of -2.48% as of Aug. 18, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on BeOne Medicines and its competitors. According to the industry distribution chart, BeOne Medicines ranks #481 out of 1387 companies in the Biotechnology industry, placing it in the top 34.7%.
Is BeOne Medicines' 3-1 Month Momentum % too high?
BeOne Medicines' current 3-1 Month Momentum % is -2.48%. Based on the distribution chart, BeOne Medicines ranks #481 out of 1387 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BeOne Medicines has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' 3-1 Month Momentum % compare to ALNY and RVMD?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #481 out of 1387 companies for 3-1 Month Momentum %. This puts BeOne Medicines in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current 3-1 Month Momentum % is -2.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
BeOne Medicines (BEIGF) has a current 3-1 Month Momentum % of -2.48%. The stock's GF Value™ is $23.68, compared to a current price of $21.95 — trading 7.3% below its estimated fair value. The current 3-1 Month Momentum % is -2.48%. BeOne Medicines' overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For BeOne Medicines (BEIGF), the current 3-1 Month Momentum % is -2.48% as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (BEIGF) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of $21.95 is trading 7.3% below its estimated GF Value™ of $23.68.
Key valuation signals for BEIGF:
3-1 Month Momentum %: -2.48%
GF Value™: $23.68 vs. price of $21.95 (7.3% below fair value)
No single metric tells the full story. See the BEIGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
77GF Score
Get the complete analysis for BEIGF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BEIGF has been successfully added to your 
